Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Renal Cell Carcinoma | Current Treatment: Physician Insights | US | 2020

Login to access report north_east
Contact sales account_box

The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the management of this disease. In a landscape previously dominated by mTOR and angiogenesis inhibitors, immune checkpoint inhibitors are experiencing rapid uptake, and the trend toward combination therapies continues to increase. The approvals in 2019 of Keytruda (Merck & Co.) plus Inlyta (Pfizer) and Bavencio (Merck KGaA / Pfizer) plus Inlyta provide alternative options for patients. These therapies will compete with Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical) and Lenvima / Kisplyx (Eisai) plus Afinitor (Novartis). As uptake of these novel regimens increases, successful drug differentiation strategies will be crucial to ensure physician uptake and preference in this rapidly changing environment.

Questions Answered

  • What are the drug-treatment rates across clinically and commercially relevant renal cell carcinoma patient populations?
  • How has the addition of immune checkpoint inhibitors changed the treatment landscape for renal cell carcinoma? Which populations are most affected?
  • How do physicians differentiate between combination therapies such as Opdivo plus Yervoy, Keytruda plus Inlyta, and Bavencio plus Inlyta? According to U.S. medical oncologists, what is the uptake of these regimens, and which combination is preferred?
  • What factors drive or constrain the prescribing habits of U.S. medical oncologists?

Product Description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Geographies: United States.

Primary Research: Survey of 100 medical oncologists in the United States.

Key drugs covered: Opdivo, Yervoy, Keytruda, Inlyta, Bavencio, Cabometyx, Sutent, Votrient, Afinitor, Lenvima.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)
Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east